Analysis of the key themes driving private equity deal activity reveals that digitalization accounted for 3 pharmaceutical deals announced in Q2 2023, worth a total value of $50.5m. The $25.5m investment by Cercano Management, Citi Impact Fund, Eldridge Products, Hearst Communications, Rethink Impact Management and Stardust Equity in Wellthy was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.

In value terms, digitalization-related deal activity decreased by 50% in Q2 2023 compared with the previous quarter’s total of $100m and rose by 1108% as compared to Q2 2022. Related deal volume increased by 50% in Q2 2023 versus the previous quarter and was 200% higher than in Q2 2022.

The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Gibson, Dunn & Crutcher; Katten Muchin Rosenman; Nixon Peabody with 1, 1, 1 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.